Acadia Pharma (NASDAQ: ACAD) today provided an update on the planned timing of its NUPLAZIDTM (pimavanserin) New Drug Application (NDA) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE